Cassava Sciences (SAVA) poses as a good buy moving forward
Cassava Sciences Inc (SAVA) currently trades at $4.81 and has grown by 14.25% today. Cassava Sciences filed a prospectus for a $200M mixed shelf offering 5 days ago. The company develops drugs using its proprietary technology. The Company develops safer and efficacious drugs for use in pain management, particularly in the area of opioid painkillers. Cassava Sciences has products in clinical trials.
Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information such as Cassava stock is up 291% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. The high forecast for Cassava Sciences Inc is $12.00 and the low is $6.00. Notably, the company’s market cap is $120.68 million with a 52 week high of $10.95 and a 52 week low of $1.00.